Drug interactions in transplant patients: What everyone should know

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 5, 2009, Pages 404-411

  Manitpisitkul, Wana ^a   McCann, Erin ^b   Lee, Sabrina ^c   Weir, Matthew R ^d  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH HOSPITAL   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Drug drug interactions; Kidney transplantation; Safety therapeutic drug monitoring

Indexed keywords

AMPHOTERICIN B; ATORVASTATIN; CALCINEURIN; CALCINEURIN INHIBITOR; CASPOFUNGIN; CYCLOSPORIN; DARUNAVIR; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; POSACONAZOLE; PRAVASTATIN; PROKINETIC AGENT; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RAPAMYCIN; SAQUINAVIR; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; COMORBIDITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENETIC TRANSCRIPTION; HUMAN; HYPERTENSION; INFECTION; KIDNEY TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; NONHUMAN; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

ANTI-INFECTIVE AGENTS; ANTICONVULSANTS; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PHARMACOKINETICS; PSYCHOTROPIC DRUGS;

EID: 69549088254     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32832edcb2     Document Type: Review

References (120)

1. Hume DM, Magee JH, Kauffman HM, et al. Renal homotransplantation in man in modified recipients. Ann Surg 1963; 158:608-644.
2. Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268:1315-1323.
3. Woodruff MF, Robson JS, Nolan B, et al. Homotransplantation of kidney in patients treated by preoperative local radiation and postoperative administration of an antimetabolite (Imuran). Lancet 1963; 2:675-682.
4. Pirsch JD, Miller J, Dierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63:977-983. (Pubitemid 27173021)
5. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64:436-443. (Pubitemid 27349884)
6. Jensik SC, and the FK 506 Kidney Transplant Study Group. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 1998; 30:1216-1218.
7. Neylan JF, for the FK 506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65:515-523.
8. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
9. Sollinger HW, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
10. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61:1029-1037.
11. Pond SM. Pharmacokinetic drug interactions. In: Benet LZ, Massoud N, Gambertoglio JG, editors. Pharmacokinetic basis for drug treatment. New York: Raven Press; 1984. pp. 195-220.
12. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 1996; 20:99-112. (Pubitemid 26281254)
13. Kelly PA, Burckar GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995; 50:1521-1535.
14. CellCept [package insert]. Nutley, New Jersey: Roche Laboratories Inc; 2008.
15. Prograf [package insert]. Deerfield, Illinois: Astellas Pharma US, Inc; 2009.
16. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interaction with cyclosporin. An update. Clin Pharmacokinet 1996; 30:141-179. (Pubitemid 126444396)
17. Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87:1322-1330. (Pubitemid 28514135)
18. Whitelock JP, Denison MS. Induction of cytochrome P450 enzymes that metabolize xenobiotics. In: Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanism and biochemistry, 2nd ed. New York: Plenum Press; 1995. pp. 367-390.
19. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001; 41:1149-1179. (Pubitemid 32983216)
20. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combine role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40:159-168. (Pubitemid 32324448)
21. Davidson MH. Dose differing metabolism by cytochrome P450 have clinical importance? Curr Atheroscler Rep 2002; 2:14-19.
22. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical applications. Clin Pharmacokinet 1998; 35:361-390. (Pubitemid 28520008)
23. Wacher J, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and cancer chemotherapy. Mol Carcinog 1995; 13:129-134.
24. Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27:161-166.
25. Bullingham R, Monroe S, Nichols A, et al. Pharmacokinetics and bioavailability of mycopheolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 36:315-324. (Pubitemid 26125953)
26. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UPD-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005; 33:139-146. (Pubitemid 40023525)
27. Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney, and jejunum microsomes. Br J Clin Pharmacol 2001; 52:605-609.
28. Hesselink DA, van Hest RM, Mathot RAA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5:987-994.
29. Van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23:119-128. (Pubitemid 32240138)
30. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006; 82:1074-1084. (Pubitemid 44632124)
31. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5:225-232. (Pubitemid 27489255)
32. Kobayashi M, Saitoh H, Tadano K, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance associated protein 2 in rats. J Pharmacol Exp Ther 2004; 309:1029-1035. (Pubitemid 38669688)
33. Westley IS, Brogan LR, Morris RC, et al. Role of MRP2 in the hepatic disposition of mycophenolic acid: effect of cyclosporine. Drug Metab Dispos 2006; 34:261-266.
34. Naderer OJ, Dupuis RE, Heinzen EL, et al. The influence of norfloxacin and metronidazole on the disposition of mycophenole mofetil. J Clin Pharmacol 2005; 45:219-226.
35. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999; 21:35-43. (Pubitemid 29077452)
36. Kagaya H, Miura M, Satoh S, et al. No pharmacokinetic interaction between mycophenolic acid and tacrolimus in renal transplant recipients. J Clin Pharm Ther 2008; 33:193-201. (Pubitemid 351341413)
37. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 65:311-321. (Pubitemid 27417797)
38. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80:1-34.
39. Gruer PJ, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P4503A inhibitors and simvastatin. Am J Cardiol 1999; 84:811-815.
40. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of microemulsion-based formulation (neural) in organ transplantation. Drugs 2001; 61:1957-2016.
41. Gullestad L, Nordal KP, Berg KJ, et al. Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transplant Proc 1999; 31:2163-2165. (Pubitemid 29376559)
42. Arnadottir M, Eriksson LO, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporine. Nephron 1993; 62:410-413. (Pubitemid 23321239)
43. Regazzi MB, Iacona I, Campana C, et al. Clinical efficacy and pharmacokinetics of HMB-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 1994; 26:2644-2645. (Pubitemid 24329263)
44. Park JW, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporine A. Int J Clin Pharmacol Ther 2002; 10:439-450.
45. Åsberg A. Interaction between cyclosporine and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63:367-378. (Pubitemid 36259524)
46. Lemahieu WPD, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interaction with tacrolimus. Am J Transplant 2005; 5:2236-2243.
47. Teichner E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46:941-952. (Pubitemid 47548643)
48. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonatvir (Kaletra) on tacrolimus blood concentration transplantation patients. Liver Transpl 2003; 9:954-960. (Pubitemid 37098844)
49. Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003; 37:1793-1796. (Pubitemid 37466573)
50. Mertz D, Battegay M, Marzolini C, et al. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. Am J Kidney Dis 2009 (in press). An important new review on transplant patients receiving antiretroviral therapy.
51. Hardy G, Stanke-Labesque F, Contamin C, et al. Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report. Eur J Clin Pharmacol 2004; 60:603-605. (Pubitemid 39517915)
52. Schvarcz R, Rudbeck G, Soderdahl G, Ståhle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000; 69:2194-2195. (Pubitemid 30395060)
53. Jain A, Venkataramanan R, Shapiro R, et al. The interaction between anti-retroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8:841-845. (Pubitemid 35012297)
54. Franssetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80:13-17. (Pubitemid 40980889)
55. Vogel M, Voigt E, Michaelis H, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10:939-944. (Pubitemid 38979268)
56. Jain A, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in liver transplantation patient: a case report. Liver Transpl 2002; 8:838-840. (Pubitemid 35012296)
57. Fischer SA. Infections in the transplant recipient. Med Health R I 2002; 85:125-127.
58. Patel R. Infections in recipients of kidney transplant. Infect Dis Clin North Am 2001; 15:901-952.
59. Cavallo R, Merlino C, Re D, et al. B19 virus infection in renal transplant recipients. J Clin Virol 2003; 26:361-368. (Pubitemid 36294114)
60. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of literature. Clin Infect Dis 2001; 32:358-366. (Pubitemid 32173620)
61. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16:607-612.
62. Singh N. Fungal infections in recipients of solid organ transplantation. Infect Dis Clin North Am 2003; 17:113-134. (Pubitemid 36514573)
63. Hagerty JA, Ortiz J, Reich D, et al. Fungal infections in solid organ transplant patients. Surg Infect 2003; 4:263-271. (Pubitemid 37428280)
64. Abraham MA, Thomas PP, John GT, et al. Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients. Transplant Proc 2003; 35:215-216.
65. Butman SM, Wild JC, Nolan PE, et al. Prospective study of safety and financial benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J Heart Lung Transplant 1991; 10:351-358.
66. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in real transplant recipients. Transplantation 1991; 51:365-370.
67. Sobh MA, Hamdy AF, El-Agroudy AE, et al. Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: long-term evaluation and study of metabolic consequences. Am J Kidney Dis 2001; 37:510-517.
68. El-Agroudy A, Sobh M, Hamdy A, Ghoneim M. A prospective, randomized study of coadministration of ketoconazole and cyclosporine A in kidney transplant recipients: ten-year follow-up. Transplantation 2004; 77:1371-1376. (Pubitemid 38668429)
69. Romero M, Latorre A, Manzanares C, et al. Effect of fluconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71:226-234. (Pubitemid 34311451)
70. Vfend [package insert]. New York, New York: Pfizer Inc; 2008.
71. Kowazoe H, Takiguchi Y, Tanaka H, et al. Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogenic hematopoietis stem cell transplantation. Biol Pharm Bull 2006; 29:2528-2531. (Pubitemid 44885883)
72. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:552-559. (Pubitemid 43956360)
73. Saad A, Depestel D, Carver P. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26:1730-1744. (Pubitemid 44885328)
74. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27:825-834. (Pubitemid 46849426)
75. Noxafil [package insert]. Kenilworth, New Jersey: Schering-Plough Corp; 2006.
76. Cancidas [package insert]. Whitehouse Station, New Jersey: Merck & Co., Inc; 2008.
77. Saner F, Gensicke J, Rath P, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006; 34:328-332. (Pubitemid 44968925)
78. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporine A. Transpl Infect Dis 2004; 6:110-116. (Pubitemid 40013050)
79. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34:13-20. (Pubitemid 39022952)
80. Christopeit M, Eikam M, Bhre G. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity. Mycoses 2008; 51 (Suppl 1):19-24. A useful review on the interaction of a new antifungal medicine with cyclosporine. (Pubitemid 351678032)
81. Morrissey CO, Slavin MA, O'Reilly MA, et al. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. Mycoses 2007; 50 (Suppl 1):24-27.
82. Mycamine [package insert]. Deerfield, Illinois: Astellas Pharma US, Inc; 2008.
83. Dowell JA, Stogniew M, Krause D, et al. Assessment of safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45:227-233. (Pubitemid 40490447)
84. Dowell JA, Stogniew M, Krause D, et al. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007; 47:305-314. (Pubitemid 46294710)
85. Perfect JR. New antifungal agents. Transplant Infect Dis 2002; 4 (Suppl 3):52-61.
86. Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002; 49 (Suppl 1):81-86. (Pubitemid 34162663)
87. Imuran [package insert]. Greenville, North Carolina: Prometheus Lab Inc; 2008.
88. Wandel C, Bohrer H, Bocker R. Rifampicin and cyclosporine dosing in heart transplant recipients. J Cardiothorac Vasc Anesth 1995; 9:621-622.
89. Kim YH, Yoon YR, Kim YW, et al. Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis. Transplant Proc 1998; 30:3570-3572.
90. Al-Sulaiman MG, Dhar JM, al-Khader AA. Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine. Transplantation 1990; 50:597-598.
91. Hebert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52:453-457.
92. Freitag V, Skiftono RD, Lake KD. Effect of short-term rifampin on stable cyclosporine concentrations. Ann Pharmacol 1999; 33:871-872. (Pubitemid 29387670)
93. Moreno M, Latorre A, Manzanares C, et al. Clinical management of tacrolimus drug interactions in renal transplant patients. Transplant Proc 1999; 31:2252-2253. (Pubitemid 29433897)
94. Chenhsu R, Loong C, Chou M, et al. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacol 2000; 34:27-31. (Pubitemid 30058920)
95. Kuypers D, Verleden G, Naesens M, et al. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-flucuronosyltransferase. Clin Pharmacol Ther 2008; 78:81-88. An important review on the interaction between mycophenolate and the antibiotic rifampin. (Pubitemid 40956934)
96. Rocha G, Figueiredo CE, d'Avila D, et al. Depressive symptoms and kidney transplant outcome. Transplant Proc 2001; 33:3424.
97. Wright DH, Lake KD, Bruhn PS, et al. Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 1999; 18:913-915.
98. Helms-Smith KM, Curtis SL, Hatton RC. Apparent interaction between nefazodone and cyclosporine. Ann Intern Med 1996; 125:424.
99. Garton T. Nefazodone and CYP 3A4 interactions with cyclosporine and tacrolimus. Transplantation 2002; 74:745.
100. Olyaei AJ, DeMattos Am, Norman DJ, et al. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy 1998; 18:1356-1359. (Pubitemid 28533893)
101. Campo JV. Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent. Arch Gen Psychiatry 1998; 55:1050-1052.
102. Richelson E. Pharmacokinetic interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997; 72:835-847. (Pubitemid 27382924)
103. Lill J, Bauer L, Horn J, et al. Cyclosporine-drug interactions and the influence of patient age. Am J Health Syst Pharm 2000; 57:1579-1584. (Pubitemid 30677348)
104. Markowitz JS, Gill HS, Hunt NM, et al. Lask of antidepressant- cyclosporine pharmacokinetics interactions. J Clin Psychopharmacol 1998; 18:91-93.
105. Liston HL, Markowitz JS, Hunt N, et al. Lack of citalopram effect on the pharmacokinetics of cyclosporine. Psychosomatics 2001; 42:370-372. (Pubitemid 32692119)
106. Strouse TB, Fairbanks LA, Skotzko CE, et al. Fluoxetine and cyclosporine in organ transplantation. Psychosomatics 1996; 37:23-30.
107. Ereshefsky K, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000; 12:30-44. (Pubitemid 30823409)
108. Wang PW, Ketter TA. Pharmacokinetics of mood stabilizers and new anti-convulsants. Psychopharmacol Bull 2002; 36:44-66.
109. Willmore LJ. Clinical pharmacology of new antiepileptic drugs. Neurology 2000; 55:S17-S24.
110. Thompson PA, Mosley CA. Tacrolimus-phenytoin interaction. Ann Pharmacother 1996; 30:544.
111. Fridell JA, Jain K, Patel K, et al. Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: case report. Ther Drug Monit 2004; 25:117-119. (Pubitemid 36139837)
112. Koomans HA, Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 2001; 27:S9-S12. (Pubitemid 32927788)
113. Olyaei AJ, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs 1999; 58:1011-1027.
114. Bunnag S, Vareesangthip K, Ong-ajyooth L. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation. J Med Assoc Thai 2006; 89 (Suppl 2):S228-S234. (Pubitemid 44903888)
115. Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002; 41:381-388.
116. Bottiger Y, Sawe J, Brattstrom C, et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther 2001; 69:32-40. (Pubitemid 32108669)
117. Seifeldin RA, Marcos-Alvarez A, Gordon FD, et al. Nifedipine interaction with tacrolimus in liver transplant recipient. Ann Pharmacother 1997; 31:571-575. (Pubitemid 27203954)
118. Lewis JB, Heldermann JH. Is it time for ACE inhibitors in chronic allograft nephropathy? Am J Kidney Dis 2000; 35:154-156.
119. Bader FM, Hagan ME, Crompton JA, et al. The effect of beta-blocker use on cyclosporine level in cardiac transplant recipients. J Heart Lung Transplant 2005; 24:2144-2147. (Pubitemid 41814738)
120. Amioka K, Kuzuya T, Kushihara H, et al. Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transplant. J Pharm Pharmacol 2007; 59:1383-1387. (Pubitemid 47606453)